Medicines watchdog decries political interference in funding of Pembro

Pembro, the drug used to treat cervical cancer, is not value for money and there is limited evidence to support its use, according to the medicines watchdog.

Professor Michael Barry, who leads the National Centre for Pharmacoeconomics (NCPE), said the money used to fund the drug would be better spent elsewhere in the health service.

Writing in this newspaper today, Barry warns that the government’s decision to fund the drug could “compromise the ...